Insulin Resistance - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Insulin Resistance - Pipeline Review, H2 2018’, provides an overview of the Insulin Resistance pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance

- The report reviews pipeline therapeutics for Insulin Resistance by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Insulin Resistance therapeutics and enlists all their major and minor projects

- The report assesses Insulin Resistance therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Insulin Resistance

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Insulin Resistance

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

BioElectron Technology Corp

Caelus Health

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

NorthSea Therapeutics BV

Pfizer Inc

Sanofi

Amgen Inc

BioElectron Technology Corp

Caelus Health

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

NorthSea Therapeutics BV

Pfizer Inc

Sanofi

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Insulin Resistance - Overview

Insulin Resistance - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Insulin Resistance - Overview

Insulin Resistance - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Resistance - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Resistance - Companies Involved in Therapeutics Development

Amgen Inc

BioElectron Technology Corp

Caelus Health

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

NorthSea Therapeutics BV

Pfizer Inc

Sanofi

Insulin Resistance - Drug Profiles

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BioE-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDN-1163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

englerin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FC-98 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Target hOGG1 for Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7992 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target AGTR1 and PPAR Gamma for Hypertension and Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Inmmunology, Metabolic Disorders and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYM-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-25659 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Resistance - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Insulin Resistance, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Insulin Resistance, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Insulin Resistance - Pipeline by Amgen Inc, H2 2018

Insulin Resistance - Pipeline by BioElectron Technology Corp, H2 2018

Insulin Resistance - Pipeline by Caelus Health, H2 2018

Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H2 2018

Insulin Resistance - Pipeline by NorthSea Therapeutics BV, H2 2018

Insulin Resistance - Pipeline by Pfizer Inc, H2 2018

Insulin Resistance - Pipeline by Sanofi, H2 2018

Insulin Resistance - Dormant Projects, H2 2018

Insulin Resistance - Dormant Projects, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Insulin Resistance, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Insulin Resistance, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports